# A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

> **NCT01691898** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 231 (actual)

## Conditions studied

- Follicular Lymphoma
- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Pinatuzumab Vedotin
- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01691898
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-27
- **Primary completion:** 2017-03-08
- **Final completion:** 2019-02-07
- **Target enrollment:** 231 (ACTUAL)
- **Last updated:** 2020-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01691898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01691898, "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01691898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*